The results showed that ATG5 high expression HNSCC patients had a higher TIDE score (p < 0.05, Figure 5D), predicted poor efficacy of ICB therapy, and poor survival after receiving ICB treatment. Here, ATG5 is linked to head and neck squamous cell carcinoma.